Press Releases

Month Year

Month Year

Sep 6, 2017

Insmed Announces Pricing of Public Offering of Common Stock

Read more
Sep 5, 2017

Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)

Study met primary endpoint of culture conversion (p < 0.0001)

Read more
Sep 5, 2017

Insmed Announces Proposed Public Offering of Common Stock

Read more
Aug 3, 2017

Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update

On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month

Read more
Jul 27, 2017

Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017

Read more
Jul 12, 2017

Insmed to Host Analyst and Investor Day on July 19, 2017

Read more
Jun 13, 2017

Insmed to Present at the JMP Securities Life Sciences Conference

Read more
Jun 8, 2017

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
May 15, 2017

Insmed Announces Key Additions to its Executive Management Team

Paolo Tombesi named as Chief Financial Officer

Read more
May 3, 2017

Insmed Reports First Quarter 2017 Financial Results and Provides Business Update

Advancing Toward Top-Line Results from CONVERT Study in 2H 2017

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation